Cutaneous T-cell lymphoma (CTCL) is a disease entity characterized by a primary sporadic T-cell proliferation in the skin. Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/lymphoma. Recently, several authors have detected the HTLV-1 genome in genomic DNA from patients with CTCL and proposed a causal relation of HTLV-1 to CTCL. However, it remains controversial because these studies contain some problems in materials used to detect HTLV-1. We investigated both fresh and cultured T lymphocytes (128 specimens) derived from 50 Japanese patients with CTCL, where HTLV-1 is endemic, by using polymerase chain reaction with four sets of primers including gag,pol,env, and pX regions of HTLV-1 to elucidate the relationship between HTLV-1 and CTCL in Japan. However, none of the 128 DNA specimens revealed positive for HTLV-1 in contrast to the previous studies. We conclude that CTCL, which does not include HTLV-1, is present although the pathogenesis of CTCL may be different by areas or races. © 1997 by The American Society of Hematology.

Topics:
adult t-cell lymphoma/leukemia, human t-lymphotropic virus 1, leukemia-lymphoma, t-cell, acute, htlv-i-associated, lymphoma, t-cell, cutaneous, viruses, dna, polymerase chain reaction, plasma exchange, lymphoma, genome

CUTANEOUS T-cell lymphoma (CTCL) is a disease entity characterized by a primary sporadic T-cell proliferation in the skin, which includes mycosis fungoides (MF ), Sezary syndrome (SS), and other peripheral T-cell lymphomas primarily occurred in the skin.1 Clinical appearance of CTCL varies from indurated patches to multiple tumors of the skin but limitation to the skin is common.2 The disease progression is indolent and dissemination of the tumor cells to the internal organ means a terminal event.2,3 Morphologically, the tumor cells are large but usually uniform in size and their nuclei show cerebriform, expressing CD4+/helper phenotype.3 In addition to these characteristics detection of the DNA rearrangement of the T-cell receptor without the monoclonal integration of human T-lymphotropic virus type 1 (HTLV-1) genome is essential in the diagnosis. Patients with CTCL are seronegative for HTLV-1 except CTCL patients in HTLV-1 carrier,3a and CTCL is considered to be sporadic.2,3 

HTLV-1 is a type of retrovirus first detected in human tumors,4 which causes adult T-cell leukemia/lymphoma (ATLL), a neoplasm of the mature T-lymphocyte.5 Patients with ATLL are seropositive for HTLV-1 and often develop a rapid dissemination to the internal organs from the early-stages.6 Skin manifestation of ATLL constitutes papules or multiple skin nodules, but sometimes show indurated erythema or erythroderma as seen in CTCL. The tumor cells, expressing CD4+/suppressor phenotype, are heterogenous in size and their nuclei have irregular contours showing flower-like arrangements.5 The prognosis of ATLL is very poor.6 

Involvement of the skin characterizes both disorders, making it difficult to differentiate between them. Furthermore, several authors have recently shown the HTLV-1 genome in the genomic DNA from patients with CTCL and proposed a causal relation between HTLV-1 and CTCL,7-12 which causes more confusions in the diagnosis as well as the meaning of HTLV-1 in these two disorders. However, in these studies there were some problems in the diagnosis of CTCL as well as in the interpretation of the laboratory data as follows: (1) The diagnoses of CTCL was not always differentiated from chronic or smouldering ATLL,12-14 (2) HTLV-1 carriers (seropositive for HTLV-1) were included in some ploymerase chain reaction (PCR) studies,12 (3) Conditions (stringency) of PCR varied,11 (4) Samples employed in these studies varied including fresh lesional skin, peripheral blood mononuclear cells (PBMC) and cultured cell lines,7-12 (5) Non-T–cell lines established from patients with CTCL were used to detect HTLV-1.7,9,15,16 

In an endemic area of ATLL like Japan diagnoses of CTCL are very critical because the treatment as well as the prognosis of ATLL are quite different from those of CTCL. Thus, in this study, we examined 128 DNA specimens of fresh lesional skin, PBMC, and T-lymphocyte clones derived from 50 Japanese patients with CTCL, who showed typical clinical and histopathological features and had no serum HTLV-1 antibodies to clarify the relationship between HTLV-1 and CTCL in Japan.

Selection of patients.We have selected 50 patients with CTCL, in which clinical features, pathological findings and DNA analyses were all typical for CTCL and serum anti-HTLV-1 antibodies were negative in both particle agglutination and enzyme-linked immunosorbent assay (ELISA) methods. The patients included 28 men and 22 women and the ages varied from 24 to 88 (mean; 55.9). The diagnoses of the patients included erythema stage of MF (n = 9), plaque stage of MF (n = 9), tumor stage of MF (n = 7), SS (n = 4), primary cutaneous anaplastic large cell lymphoma of T-cell type expressing Ki-1 (CD30) antigen (Ki-1+CTCL) (n = 4), CTCL other than MF, SS, or Ki-1+CTCL (n = 17). A case of smouldering ATLL in which monoclonal integrations of HTLV-1 genome were proved by Southern blot analysis and two cases of serum anti-HTLV-1 antibody positive CTCL in which monoclonal integrations of HTLV-1 genome were not detected (CTCLs in HTLV-1 carrier),3a were employed as positive controls.

Cell culture.The fresh skin specimens from the patients with CTCL were incubated in RPMI medium 1640 containing 20% fetal bovine serum and interleukin-2 after an initial 72-hour stimulation with phytohemagglutinin. When the cultured cells once constantly grew in the medium, phenotypic analyses were done by using flow cytometry with anti-CD4 monoclonal antibody. If the cultured cells express CD4 on their surface, genomic DNAs were derived for the subsequent PCR.

Table 1.

Primers Used for Amplification of HTLV-1

RegionPrimer Nucleotide SequenceProduct Size
gag sense 5′-TATGCAGACCATCCGGCTTG-3′ (1324-1343) 
 anti-sense 5′-TTGTTGGCTTGGACACGGAG-3′ (1521-1502) 198 bp 
pol sense 5′-AGGCCTTGCAACACTTGGTC-3′ (2631-2650) 
 anti-sense 5′-GGATGAATCGCCAGGTTCCA-3′ (2750-2731) 120 bp 
env sense 5′-TCGACGCTCCAGGATATGAC-3′ (5696-5715) 
 anti-sense 5′-GAGGCTGGCACGATCGATAC-3′ (5904-5885) 209 bp 
pX sense 5′-GGCTCCGTTGTCCGCATGTA-3′ (7764-7783) 
 anti-sense 5′-AATCATAGGCGTGCCATCGG-3′ (8090-8071) 327 bp 
RegionPrimer Nucleotide SequenceProduct Size
gag sense 5′-TATGCAGACCATCCGGCTTG-3′ (1324-1343) 
 anti-sense 5′-TTGTTGGCTTGGACACGGAG-3′ (1521-1502) 198 bp 
pol sense 5′-AGGCCTTGCAACACTTGGTC-3′ (2631-2650) 
 anti-sense 5′-GGATGAATCGCCAGGTTCCA-3′ (2750-2731) 120 bp 
env sense 5′-TCGACGCTCCAGGATATGAC-3′ (5696-5715) 
 anti-sense 5′-GAGGCTGGCACGATCGATAC-3′ (5904-5885) 209 bp 
pX sense 5′-GGCTCCGTTGTCCGCATGTA-3′ (7764-7783) 
 anti-sense 5′-AATCATAGGCGTGCCATCGG-3′ (8090-8071) 327 bp 

Complete proviral sequences is described elsewhere.25 

View Large
Table 2.

Summary of the Clinical Data, Serum Antibodies, and PCR Studies

Age/SexDiagnosisSerum AntibodiesDetection of HTLV-1 DNA
PAELISASkinPBMCT-Cell Clones
gagpolenvpxgagpolenvpXgagpolenvpX
1 57 m MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
2 45 m MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
3 33 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
4 54 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
5 55 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
6 28 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
7 46 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
8 68 m MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
9 24 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
10 72 m MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
11 69 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
12 45 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
13 58 m MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
14 53 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
15 81 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
16 88 f MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
17 75 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
18 50 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
19 29 m MF t  —  <0.395  —   —   —   —  nd nd 
                 
20 26 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
21 41 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
22 50 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
23 77 f MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
24 53 m MF t  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
25 46 m MF t  —  <0.395  —   —   —   —  nd  —   —   —   —  
                 
26 77 f SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
27 57 m SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
28 87 f SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
29 45 m SS  —  <0.395  —   —   —   —  nd nd 
                 
30 42 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
31 70 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
32 43 m Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
33 54 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
34 55 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
35 63 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
36 65 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
37 77 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
38 65 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
39 34 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
40 54 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
41 85 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
42 80 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
43 45 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
44 49 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
45 53 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
46 88 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
47 35 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
48 48 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
49 29 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
50 70 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
51 65 m sATLL +  2.20< ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
52 54 m CTCL+ +  2.16 + + + + + + + + + + + + 
53 59 f CTCL+ +  0.94 + + + + + + + + + + + + 
Age/SexDiagnosisSerum AntibodiesDetection of HTLV-1 DNA
PAELISASkinPBMCT-Cell Clones
gagpolenvpxgagpolenvpXgagpolenvpX
1 57 m MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
2 45 m MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
3 33 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
4 54 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
5 55 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
6 28 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
7 46 f MF e  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
8 68 m MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
9 24 f MF e  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
10 72 m MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
11 69 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
12 45 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
13 58 m MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
14 53 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
15 81 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
16 88 f MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
17 75 f MF p  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
18 50 m MF p  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
19 29 m MF t  —  <0.395  —   —   —   —  nd nd 
                 
20 26 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
21 41 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
22 50 m MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
23 77 f MF t  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
24 53 m MF t  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
25 46 m MF t  —  <0.395  —   —   —   —  nd  —   —   —   —  
                 
26 77 f SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
27 57 m SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
28 87 f SS  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
29 45 m SS  —  <0.395  —   —   —   —  nd nd 
                 
30 42 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
31 70 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
32 43 m Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
33 54 f Ki-1+CTCL  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
34 55 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
35 63 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
36 65 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
37 77 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —  ne 
                 
38 65 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
39 34 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
40 54 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
41 85 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
42 80 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
43 45 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
44 49 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
45 53 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
46 88 m CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
47 35 m CTCL*  —  <0.395  —   —   —   —  nd nd 
                 
48 48 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
49 29 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
50 70 f CTCL*  —  <0.395  —   —   —   —   —   —   —   —   —   —   —   —  
51 65 m sATLL +  2.20< ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
52 54 m CTCL+ +  2.16 + + + + + + + + + + + + 
53 59 f CTCL+ +  0.94 + + + + + + + + + + + + 

Abbreviations: PA, particle agglutination; ELISA, enzyme-linked immunosorbent assay (cut off < 0.395); PBMC, peripheral blood mononuclear cells; nd, not done; ne, not established; MF, mycosis fungoides (e, erythema stage; p, plaque stage; t, tumor stage); SS, Sezary syndrome; Ki-1+CTCL, primary cutaneous anaplastic large cell lymphoma of T-cell type expressing Ki-1 (CD30) antigen; CTCL*, cutaneous T-cell lymphoma other than MF, SS, or Ki-1+CTCL; CTCL+, CTCL in HTLV-1 carrier; sATLL smouldering adult T-cell leukemia/lymphoma.

View Large
Fig. 1.
Fig. 1. Results of PCR for HTLV-1. In smouldering ATLL (case no. 51), strongly positive bands were detected with all four sets of primers (lanes 1 through 4). In CTCLs in HTLV-1 carrier (case nos. 52 and 53), weakly positive bands were detected with all four sets of primers (lanes 5 through 8). In 50 CTCLs, no bands were detected for HTLV-1 (lanes 9 through 12). M: molecular marker; lanes 1 and 5; gag (198 base pairs [bp]), lanes 2 and 6; pol (120 bp), lanes 3 and 7; env (209 bp), lanes 4 and 8; pX (327 bp).
View largeDownload PPT

Results of PCR for HTLV-1. In smouldering ATLL (case no. 51), strongly positive bands were detected with all four sets of primers (lanes 1 through 4). In CTCLs in HTLV-1 carrier (case nos. 52 and 53), weakly positive bands were detected with all four sets of primers (lanes 5 through 8). In 50 CTCLs, no bands were detected for HTLV-1 (lanes 9 through 12). M: molecular marker; lanes 1 and 5; gag (198 base pairs [bp]), lanes 2 and 6; pol (120 bp), lanes 3 and 7; env (209 bp), lanes 4 and 8; pX (327 bp).

Fig. 1.
Fig. 1. Results of PCR for HTLV-1. In smouldering ATLL (case no. 51), strongly positive bands were detected with all four sets of primers (lanes 1 through 4). In CTCLs in HTLV-1 carrier (case nos. 52 and 53), weakly positive bands were detected with all four sets of primers (lanes 5 through 8). In 50 CTCLs, no bands were detected for HTLV-1 (lanes 9 through 12). M: molecular marker; lanes 1 and 5; gag (198 base pairs [bp]), lanes 2 and 6; pol (120 bp), lanes 3 and 7; env (209 bp), lanes 4 and 8; pX (327 bp).
View largeDownload PPT

Results of PCR for HTLV-1. In smouldering ATLL (case no. 51), strongly positive bands were detected with all four sets of primers (lanes 1 through 4). In CTCLs in HTLV-1 carrier (case nos. 52 and 53), weakly positive bands were detected with all four sets of primers (lanes 5 through 8). In 50 CTCLs, no bands were detected for HTLV-1 (lanes 9 through 12). M: molecular marker; lanes 1 and 5; gag (198 base pairs [bp]), lanes 2 and 6; pol (120 bp), lanes 3 and 7; env (209 bp), lanes 4 and 8; pX (327 bp).

Close modal

DNA preparation.Genomic DNAs were derived from the fresh lesional skin and PBMC of the patients with CTCL. Briefly, after phenol chloroform extraction the DNA was precipitated with ethanol and redissolved in sterile H2O. DNA concentration was estimated by absorption at 260 nm.

PCR amplification.Amplification of the DNA was performed in a total volume of 50 μL in a reaction mixture containing 225 μmol/L each of deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate, 50 to 125 pmol each of primer, 50 mmol/L KCl, 2.5 mmol/L MgCl2 , and 10 mmol/L tris-HCl (pH 8.3), and 2 U of Taq polymerase (Takara, Shiga, Japan). Solutions were covered with mineral oil to prevent condensation. Fifty cycles of denaturation 2 minutes at 94°C, primer anealing for 1 minute at 60°C, and chain elongation for 30 seconds at 72°C were performed, using reagents from Takara Gene Amp reagents kit and the Perkin Elmer Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). The primers used for the amplification of HTLV-1 are shown in Table 1.

T-cell cultures were established in 4 cases of erythema stage MF, 5 of plaque stage MF, 5 of tumor stage MF, 3 of SS, 4 of Ki-1+ CTCL, and 13 of CTCL other than MF, SS, or Ki-1+ CTCL. Totally, 128 DNA samples were taken from 50 lesional skin, 44 PBMC and 34 cultured T-lymphocyte clones. The results are summarized in Table 2. No samples revealed positive for HTLV-1 genome. Two CTCLs in HTLV-1 carrier revealed positive with all four sets of primers and a smouldering ATLL revealed strongly positive with all sets of primers examined (Fig 1).

In Japan, where has the highest prevalence of HTLV-1 infection in the world, antibodies against HTLV-1 have been detected in 1.2 million people (most of them are carriers of HTLV-1), which are estimated at approximately 1.0% of all Japanese population, and newly more than 700 cases of ATLL are diagnosed each year.6 Thus, the presence of serum HTLV-1 antibodies is not diagnostic for ATLL and it is essential to confirm the monoclonal integration of the HTLV-1 DNA by using Southern blot analysis17 or inverse PCR,18 a newly developed method to recognize the monoclonality of HTLV-1 under the detection level of Southern blotting. In practice, such borderline cases as a smouldering ATLL showing indolent MF-like course (our no. 51), HTLV-1 negative ATLL,19 and CTCLs accompanied by serum anti-HTLV-1 antibodies (our nos. 52 and 53)3a are present.

In lymphoproliferative disorders except ATLL the seronegativity for HTLV-1 is common. However, more sensitive method such as ELISA has recently enabled to show positivity for HTLV-1 up to 30% in various leukemia/lymphoma patients including MF.20,21 In certain regions of the United States HTLV-1 seroprevalence has been particularly high in prostitutes, homosexuals, and intravenous drug users.22,23 These tendencies are completely different from our backgrounds (patients who have serum anti-HTLV-1 antibodies are exceptional in our series), and they also suggest the higher detection rates of HTLV-1 genome in their PCR studies. As shown in Fig 1, it is reasonable that the PCR for HTLV-1 revealed positive in HTLV-1 carriers (but the positive bands were weaker than those in smouldering ATLL), which should not be included into these HTLV-1 detection studies. Moreover, it is no doubt that patients having monoclonal integrations of HTLV-1 should be diagnosed as ATLL.17 

In addition to these confusions in the diagnoses of ATLL and in the interpretation of serum anti-HTLV-1 antibodies, there are several problems in the positive HTLV-1 results with PCR in CTCL. First, technical errors including contamination can easily occur especially in PCR studies. Second, many positive bands can be detected if the stringency of PCR is low (data not shown). These results indicate the presence of endogenous HTLV-1–like sequences within human genomic DNA or the detection of other retroviral sequences similar to HTLV-1 (HTLV-5, etc). Moreover, the false positive results for HTLV-1 can be detected unless the complete sequencings for the PCR products are done.11 Third, deleted forms of HTLV-1 genome may exist in the genomic DNA of CTCL patients.8 If the HTLV-1 genome was inserted into the host DNA as a deleted form, it is reasonable that the defective HTLV-1 genome neither induce the host's antibody production nor the replication of the ATL cells. Lastly, in the positive studies7-12 most of the HTLV-1 DNA were proved not in the fresh specimens but in the cultured cells including non-T–cell lines.8,16 During the cultivating procedures not only clonal expansions but also modifications of the culturing cells can occur, thus the DNA derived from those cell lines does not exactly reflect the conditions in the original CTCL. Furthermore, HTLV-1 sequences have been detected even in squamous cell carcinoma of the skin,24 suggesting that an opportunistic or a coincidental infection of HTLV-1 should be considered.

We conclude that CTCL which does not include HTLV-1 is present although the pathogenesis of CTCL may be different by respective areas or races.

Address reprint requests to Arata Kikuchi, MD, PhD, Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160, Japan.

1
Edelson
RL
Cutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome and other variants).
J Am Acad Dermatol
2
1980
89
Google Scholar
Crossref
Search ADS
PubMed
 
2
Kikuchi
A
Sakuraoka
K
Kurihara
S
Akiyama
M
Shimizu
H
Nishikawa
T
CD8+ cutaneous anaplastic large cell lymphoma.
Br J Dermatol
126
1992
404
Google Scholar
Crossref
Search ADS
PubMed
 
3
Kikuchi
A
Shimizu
H
Nishikawa
T
Cutaneous T-cell lymphoma arising from parakeratosis variegata.
Dermatology
190
1995
124
Google Scholar
Crossref
Search ADS
PubMed
 
3a
Kikuchi A, Ohata Y, Matsumoto H, Sugiura M, Nishikawa T: Anti-HTLV-1 antibody positive cutaneous T-cell lymphoma. Cancer (in press)
4
Poiesz
BJ
Ruscetti
FW
Gazdar
AF
Bunn
PA
Minna
JD
Gallo
RC
Detection and isolation of type C retrovirus particles of from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.
Proc Natl Acad Sci USA
50
1980
7415
Google Scholar
Crossref
Search ADS
 
5
Uchiyama
T
Yodoi
J
Sagawa
K
Takatsuki
K
Uchino
H
Adult T-cell leukemia; clinical and hematological features of 16 cases.
Blood
50
1977
481
Google Scholar
Crossref
Search ADS
PubMed
 
6
Yamaguchi
K
Human T-lymphotropic virus type I in Japan.
Lancet
343
1994
213
Google Scholar
Crossref
Search ADS
PubMed
 
7
Anagnostopoulos
I
Hummel
M
Kaudewitz
P
Herbst
H
Braun-Falco
O
Stein
H
Detection of HTLV-1 proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas.
Am J Pathol
137
1990
1317
Google Scholar
PubMed
 
8
Hall
WW
Liu
CR
Schneewind
O
Takahashi
H
Kaplan
MH
Roupe
G
Vahlne
A
Deleted HTLV-1 provirus in blood and cutaneous lesions of patients with mycosis fungoides.
Science
253
1991
317
Google Scholar
Crossref
Search ADS
PubMed
 
9
Zucker-Franklin
D
Coutavas
EE
Rush
MG
Zouzias
DC
Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes of patients with mycosis fungoides.
Proc Natl Acad Sci USA
88
1991
7630
Google Scholar
Crossref
Search ADS
PubMed
 
10
Srivastava
BIS
Banki
K
Pearl
A
Human T-cell leukemia virus type I or a related retrovirus in patients with mycosis fungoides/Sezary syndrome and Koposi's sarcoma.
Cancer Res
52
1992
4391
Google Scholar
PubMed
 
11
Whittaker
SJ
Luzzatto
L
HTLV-1 provirus and mycosis fungoides.
Science
259
1993
8175
Google Scholar
Crossref
Search ADS
 
12
Pancake
BA
Zucker-Franklin
D
Coutavas
EE
The cutaneous T-cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease.
J Clin Invest
95
1995
547
Google Scholar
Crossref
Search ADS
PubMed
 
13
Detmar
M
Pauli
G
Anagnostopoulos
I
Wunderlich
U
Herbst
H
Garbe
C
Stein
H
Orfanos
CE
A case of classical mycosis fungoides associated with human T-cell lymphotropic virus type I.
Br J Dermatol
124
1991
198
Google Scholar
Crossref
Search ADS
PubMed
 
14
Bunker
CB
Whittaker
S
Luzzatto
L
Gore
ME
Rustin
MHA
Smith
NP
Levene
GM
Indolent cutaneous prodrome of fatal HTLV-1 infection.
Lancet
335
1990
426
Google Scholar
Crossref
Search ADS
PubMed
 
15
Manzari
V
Gismondi
G
Barillari
S
Morrone
A
Modesti
A
Albonici
L
DeMarchis
L
Fazio
V
Gradilone
A
Zani
M
Frati
L
Santoni
A
HTLV-V: A new human retrovirus isolated in a Tac-negative T-cell lymphoma/leukemia.
Science
238
1977
1581
Google Scholar
Crossref
Search ADS
 
16
Manca
N
Piacentini
E
Gelmi
M
Calzavara
P
Manganoni
MA
Glukhov
A
Gargiulo
F
De Francesco
M
Pirali
F
De Panfilis
G
Turano
A
Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides.
J Exp Med
180
1994
1973
Google Scholar
Crossref
Search ADS
PubMed
 
17
Yamaguchi
K
Seiki
M
Yoshida
M
Nishimura
H
Kawano
F
Takatsuki
K
The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy.
Blood
63
1984
1235
Google Scholar
Crossref
Search ADS
PubMed
 
18
Takemoto
S
Matsuoka
M
Yamaguchi
K
Takatsuki
K
A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction.
Blood
84
1994
3080
Google Scholar
Crossref
Search ADS
PubMed
 
19
Shimoyama
M
Kagami
Y
Shimotohno
K
Miwa
M
Minato
K
Tobinai
K
Suemasu
K
Sugimura
T
Adult T-cell leukemia/lymphoma not associated with human T-cell leukemia virus type I.
Proc Natl Acad Sci USA
83
1986
4524
Google Scholar
Crossref
Search ADS
PubMed
 
20
Srivastava
BIS
Gonzales
C
Loftus
R
Fitzpatrick
JE
Saxinger
CW
Examination of HTLV-1 ELISA-positive leukemia/lymphoma patients by Western blotting gave mostly negative or intermediate reaction.
AIDS Res Human Retroviruses
6
1990
617
Google Scholar
Crossref
Search ADS
 
21
Wantzin
GL
Thomsen
K
Nissen
NI
Saxinger
C
Gallo
RC
Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma.
J Am Acad Dermatol
15
1986
598
Google Scholar
Crossref
Search ADS
PubMed
 
22
Khabbaz
RF
Darrow
WW
Hartley
TM
et al
Seroprevalance and risk factors for HTLV-I/II infection among female prostitutes in the United States.
JAMA
263
1990
60
64
Google Scholar
Crossref
Search ADS
PubMed
 
23
Robert-Guroff
M
Weiss
SH
Giron
JA
Jenning
AM
Ginzburg
HM
Margolis
IB
Blattner
WA
Gallo
RC
Prevalence of antibodies to HTLV-I, -II and -III in intravenous drug abusers from an AIDS endemic region.
JAMA
255
1986
3133
Google Scholar
Crossref
Search ADS
PubMed
 
24
Chan
WC
Hooper
C
Wickert
R
Benson
JM
Vardiman
J
Hinrichs
S
Weisenburger
D
HTLV-1 sequence in lymphoproliferative disorders.
Diagn Mol Pathol
2
1993
192
Google Scholar
Crossref
Search ADS
PubMed
 
25
The complete nucleotide sequenses of the HTLV-1 genome have been submitted to the National Center for Biotechnology Information (NCBI) databases. The accession number is J02029
Copyright © 1997 American Society of Hematology
1997
Sign in via your Institution